Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The need for disease modifying treatment [Market size and Growth & Competition] The Parkinsons disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022, it grows at a CAGR of 6.1%.(source: reportsnreports) Currently, 2 investigator initiated trials using GLP-1 agonists (lixisenatide and liraglutide) are recruiting PD patients in collaboration with CPT and VARI in France and US respectively, which will prove and support the efficacy of the GLP-1R pathway in PD
The role of the EAAT3 is to control glutamate spillover, which affects pre-synaptic N -methyl- D -aspartate (NMDA) and metabotropic glutamate receptors activity 63,64
Diabetes & Metabolism Journal, 47 (3), 315-324
In a small study, blood catalase and GSH/GSSG levels significantly increased after administration of 6000mg NAC for 6 weeks in patients with Parkinsons disease and 3 healthy participants
Alexander said he thinks obesity drugs will eventually become affordable cheap even
Current opinion in clinical nutrition and metabolic care, 26(6), 521527
